CRISPR-Cas13: A new frontier in RNA-editing with therapeutic potential
In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the ...
MIT Technology Review1d
Two Nobel Prize winners want to cancel their own CRISPR patents in Europe
But now, in a surprise twist, the team that earned the Nobel Prize in chemistry for developing CRISPR is asking to cancel two ...
News Medical on MSN1d
CRISPR-Cas13 emerges as a game changer in RNA-targeted therapies
In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the ...
FiercePharma2d
Vertex taps Lonza to help produce global supply of cutting-edge CRISPR therapy Casgevy
With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...
Innovative model using CRISPR provides valuable insights into prostate cancer spread
A new preclinical model using CRISPR, an advanced technology that allows scientists to cut and edit genes, has given Weill ...
New kit makes classroom CRISPR experiments affordable and accessible
CRISPR, the gene-editing technology, has been one of the major breakthroughs in biology in the last two decades. And while ...
Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy?
CRISPR Therapeutics' first therapy is called Casgevy. It treats sickle cell disease (SCD) and beta thalassemia, both rare inherited illnesses that affect the function of a person's red blood cells. It ...
Health Canada Oks Vertex's CASGEVY, First CRISPR/Cas9 Gene-Edited Therapy For Sickle Cell Disease
Vertex Pharmaceuticals Inc. (VRTX) said that Health Canada has granted Marketing Authorization for CASGEVY (exagamglogene ...
Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end ...
News Medical on MSN3d
The role of CRISPR-Cas9 in combating mosquito-borne diseases
Announcing a new article publication for Zoonoses journal. As global warming increases, mosquito activity areas are expanding ...
CRISPR Therapeutics (NASDAQ:CRSP) shareholders have endured a 59% loss from investing in the stock three years ago
If you love investing in stocks you're bound to buy some losers. Long term CRISPR Therapeutics AG (NASDAQ:CRSP) shareholders ...
The Scientist10d
From CRISPR to Prime Editing: The Evolution of the Genome Editing Revolution
View full profile. Learn about our editorial policies. Like the human immune system, bacteria learn from past infections. CRISPR sequences—short snippets of DNA from previous viruses—guide destructive ...